Dr Toni Choueiri speaks to ecancer about his study regarding pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma.
Initially, he talks about the background of the study. He says that KEYNOTE-564 is the first phase III study with a checkpoint inhibitor in the adjuvant setting to improve DFS for patients with high risk fully resected RCC. He then discusses the methodology of the study.
The key results included a 24 months median follow-up which showed patients receiving pembrolizumab had a 32% reduction in the risk of disease recurrence or death. The 24-month estimated DFS rate was 77.3% with pembrolizumab, compared to 68.1% with placebo. Overall, DFS benefit was consistent across subgroups.
Dr Choueiri concludes that the estimated preliminary overall survival (OS) rate at 24 months was 96.6% with pembrolizumab, compared to 93.5% with placebo. Grade 3-5 all-cause adverse events (AEs) were more common with pembrolizumab than placebo — 32.4% versus 17.7%, respectively.
Read more about the study here.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.